How to Navigate Ecosystem Connect NEW Distinguished Investigators 
Global Conferences RLT Education RLT Components Sponsors Trial Stats
Global Conferences RLT Education RLT Components Sponsors Trial Stats 
How to NavigateNEW Ecosystem Connect Distinguished Investigators Global Conferences RLT Education RLT Components Sponsors Trial Stats Dictionary About Us Our Values
Contact XCancer
Luke Nordquist, MD, FACP, CEO
drluke@xcancer.comTony Romero, MS, CCRC, Director of Research
tromero@gucancer.comThis is an open label, prospective, trial that begins with a phase Ib safety run-in followed by a phase II expansion cohort.
Description:
Phase IB Study of Nivolumab in Combination With Radium-223 in Men With Metastatic Castration Resistant Prostate Cancer. This is an open label, prospective, trial that begins with a phase Ib safety run-in followed by a phase II expansion cohort.
Sponsor:
University of Utah
Phase:
Phase 1
Government Study Link:
NCT04109729 - Click here to see study onClinicalTrials.gov
Share your feedback
Help us improve your experience